Coca-Cola Europacific Partners (CCEP) is an entrenched, high-quality bottler generating roughly $2 billion in annual free cash flow. While it operates with structurally lower margins than franchisors like KO, its local monopoly on distribution and vast scale provide a wide economic moat. It is a predictable compounder actively returning capital through dividends and buybacks. Fair value range: low $91.3, high $140, with mid-point at $116.
Đã phân tích: 2026-05-20·Cập nhật tiếp theo: 2026-08-20·Methodology v2.4·Data cut-off:·Quality gate: pass·Sources: all material sources passed deterministic freshness/provenance gates·Review: automated·Archetype: Mature compounder
Stable 13.3% operating margins prove successful pass-through of severe cost inflation.
Fair value
$116
Margin of safety
+20.6%
Confidence
88/100
Moat
9/10
Educational analysis only — not financial advice. Always do your own due diligence.
$91.86Price
Low $91.30
Mid $115.74
High $140.15
Coca-Cola Europacific Partners (CCEP) is an entrenched, high-quality bottler generating roughly $2 billion in annual free cash flow. While it operates with structurally lower margins than franchisors like KO, its local monopoly on distribution and vast scale provide a wide economic moat. It is a predictable compounder actively returning capital through dividends and buybacks.
Exclusive territorial distribution agreements for
Exclusive territorial distribution agreements for top global beverage brands.
Massive local distribution density creating
Massive local distribution density creating insurmountable scale advantages.
Our financial-history view of CCEP (CCEP) covers revenue, gross profit, operating income, and net income across the past five fiscal years, with year-over-year growth and margin context for each line.
The revenue trajectory is reported in the financial-history section with year-over-year growth rates. Direction and acceleration are summarised inline; the full table sits within the parent financials tab.
We track operating income alongside operating margin so the reader can separate top-line growth from operating leverage. The numbers analysis subsection flags one-offs, restructuring, and stock-based-compensation effects when material.
Net income is shown together with EPS so dilution and buybacks are visible alongside profit. Where reported net income diverges materially from operating cash flow, the discrepancy is called out in the numbers-analysis subsection.
FAQ
CCEP — frequently asked questions
Based on our latest analysis, CCEP looks meaningfully undervalued. The current price is $91.9 versus a composite fair-value midpoint of $116 (range $91.3–$140), which implies roughly 26.0% upside to the midpoint.
Our composite fair-value range for CCEP is $91.3–$140, with a midpoint of $116. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for CCEP's archetype.
Our current rating for CCEP is Strong Buy with a confidence score of 88/100. Strong Buy. The asset trades at an excessively pessimistic valuation despite durable local monopolies and highly visible $2B+ annual free cash flow. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for CCEP are: Elasticity Breakpoint; Franchisor Margin Extraction; Capital Intensity Spike. The single biggest risk is Elasticity Breakpoint: Consumers reject sustained price hikes, driving permanent volume declines and private label substitution.
Our current rating for CCEP is Strong Buy, issued with a confidence score of 88/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($91.3–$140) versus the current price of $91.9.
CCEP is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for CCEP.